About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

NANO MRNA Co., Ltd.(4571) Summary

4571
TSE Growth
NANO MRNA Co., Ltd.
134
JPY
+2
(+1.52%)
May 1, 3:30 pm JST
0.92
USD
May 1, 2:30 am EDT
Result
PTS
outside of trading hours
134.9
May 1, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.19
Yield
ー%
Margin Trading Ratio
Stock Price
May 1, 2025
Opening May 1, 9:00 am
132 JPY 0.92 USD
Previous Close Apr 30
132 JPY 0.92 USD
High May 1, 10:46 am
139 JPY 0.97 USD
Low May 1, 11:12 am
130 JPY 0.90 USD
Volume
3,507,700
Trading Value
0.47B JPY 3.29M USD
VWAP
135.2 JPY 0.94 USD
Minimum Trading Value
13,400 JPY 92 USD
Market Cap
9.46B JPY 0.07B USD
Number of Trades
441
Liquidity & Number of Trades
As of May 1, 2025
Liquidity
Mid
1-Year Average
251
1-Year High Aug 26, 2024
1,857
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 25, 2025 0 3,521,200
Apr 18, 2025 0 3,391,400
Apr 11, 2025 0 3,232,700
Apr 4, 2025 0 3,561,300
Mar 28, 2025 0 3,709,100
Company Profile
NANO MRNA Co., Ltd. is a biotech venture specializing in mRNA therapeutics. The company is expanding its pipeline through collaborations and partnerships, with high expectations for treating intractable cancers.
Sector
Pharmaceuticals
NANO MRNA Co., Ltd. has been developing innovative pharmaceuticals, primarily focusing on anticancer drugs that encapsulate small molecules and other medicines within nanoparticles using micellar nanoparticle technology. In January 2023, the company shifted its business model to concentrate on mRNA therapeutics. mRNA therapeutics involve administering artificially manufactured mRNA to the body, enabling the expression of proteins encoded by the mRNA to prevent or treat diseases. The company is advancing multiple mRNA pipelines, including regenerative medicine for osteoarthritis of the knee, immune tolerance vaccines, and preventive vaccines for infectious diseases. NANO MRNA conducts research and development up to the preclinical trial stage and then licenses out to pharmaceutical companies. The company actively pursues joint research with academia, pharmaceutical, and non-pharmaceutical companies to expand its pipeline of new candidates. In addition to mRNA, NANO MRNA continues to develop brain tumor treatments and siRNA drugs targeting transcription factors. The company aims to establish a development system rivaling major pharmaceutical companies and create innovative medicines.